Shanghai Pharmaceuticals' (HKG:2607, SHA:601607) unit, Shanghai Pharmaceuticals Group Biotherapy Technology, received approval from China's National Medical Products Administration for the clinical trial of B023 cell injection, according to a Shanghai bourse filing on Wednesday.
The drug will be tested as a treatment for patients with solid tumors who have failed standard treatments.